Anagenics Limited operates as a health and beauty tech company in Australia, New Zealand, and internationally. It develops and sells FGF5 inhibitor formulations; over-the-counter (OTC), cosmetic antiaging, and longevity targeting products; and imports and distributes international and local skin care and wellbeing products under the Thalgo, Hydro Peptide, Comfort Zone, Priori, and Inika Organic brand names. The company also develops, manufactures, and markets beauty and wellness brands comprising Uspa and evolis. It offers its products through various channels, including clinics, retail stores, wholesale pharmacy and spa/salons, online ecommerce, and cross border export markets. The company was formerly known as Cellmid Limited and changed its name to Anagenics Limited in December 2021. Anagenics Limited was incorporated in 2004 and is based in Sydney, Australia.
| Market Capitalization | $6.9468 million |
| P/E Ratio | 0 |
| P/E Growth Ratio | |
| Book Value | 0.028 |
| Dividend Per Share | 0 |
| Earnings Per Share | -0.01 |
| EBITDA | -1,386.676 |
| Profit Margin | -0.2927 |
| Operating Margin TTM | -0.1916 |
| Return on Assets TTM | -0.0908 |
| Return on Equity TTM | -0.2027 |
| Revenue TTM | 9,113.414 |
All numbers are in thousands
| Date | Total Revenue | Cost of Revenue | Gross Profit | Total Operating Expenses |
|---|---|---|---|---|
| 2017-06-30 | 4,722.61 | 2,118.72 | 2,603.89 | |
| 2018-06-30 | 5,647.93 | 2,169.84 | 5,647.93 | |
| 2019-06-30 | 7,301.686 | 2,137.384 | 5,164.302 | 12,195.052 |
| 2020-06-30 | 7,380.895 | 2,533.846 | 4,847.049 | 11,279.091 |
| 2021-06-30 | 5,816.351 | 2,112.683 | 3,703.668 | 8,227.839 |
| 2022-06-30 | 9,234.874 | 4,169.631 | 5,065.243 | 9,627.219 |
| 2023-06-30 | 9,113.41 | 4,701.91 | 4,411.5 |
All numbers are in thousands
| Date | Cash | Total Assets | Total Liabilities | Short Term Debt | Long Term Debt | Common Stock |
|---|---|---|---|---|---|---|
| 2017-06-30 | 3,994.64 | 8,148.39 | 4,077.37 | 0 | 314.57 | 36,715.03 |
| 2018-06-30 | 1,607.783 | 6,748.577 | 4,893.405 | 0 | 1,166.447 | 38,014.078 |
| 2019-06-30 | 3,081.924 | 9,792.134 | 3,934.857 | 266.804 | 1,019.855 | 47,765.837 |
| 2020-06-30 | 6,970.967 | 14,888.211 | 5,077.496 | 465.228 | 1,033.826 | 56,064.284 |
| 2021-06-30 | 6,727.764 | 13,293.083 | 2,858.699 | 589.852 | 601.396 | 60,280.064 |
| 2022-06-30 | 3,284.852 | 12,924.744 | 4,635.144 | 902.662 | 767.547 | 62,435.064 |
| 2023-06-30 | 2,567.061 | 11,112.12 | 2,216.69 | 0 | 0 | 65,357.15 |
All numbers are in thousands
| Date | Net Income | Total Cash | Change in Cash | Begin period cash | End period cash | Dividends |
|---|---|---|---|---|---|---|
| 2017-06-30 | -4,060.52 | 1,308.31 | 3,994.641 | |||
| 2018-06-30 | -3,732.615 | -4,163.653 | -2,386.858 | 3,994.641 | 1,607.783 | |
| 2019-06-30 | -5,909.557 | -5,671.373 | 1,474.141 | 1,607.783 | 3,081.924 | |
| 2020-06-30 | -4,907.296 | -4,013.105 | 3,889.043 | 3,081.924 | 6,970.967 | 202.19 |
| 2021-06-30 | -3,386.632 | -4,114.15 | -243.203 | 6,970.967 | 6,727.764 | 54.756 |
| 2022-06-30 | -3,648.787 | -2,525.596 | -3,442.912 | 6,727.764 | 3,284.852 | |
| 2023-06-30 | -2,667.15 | -1,758.91 | -717.79 | 3,284.852 | 2,567.061 |